替奈普酶治疗急性脑卒中：触手可及还是尚未获批？
The promise of tenecteplase in acute stroke: Within reach or beyond approval?
机构信息
Departments of Emergency Medicine (KSZ) and Neurology (LHS), Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Departments of Emergency Medicine (KSZ) and Neurology (LHS), Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Digital Patient Experience, Mass General Brigham Health System, Somerville, MA, USA.
出版信息
Med. 2022 Oct 14;3(10):651-655. doi: 10.1016/j.medj.2022.09.005. Epub 2022 Oct 5.
Reperfusion is critical for improving outcomes of patients experiencing ischemic stroke. Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.
再灌注对于改善缺血性脑卒中患者的预后至关重要。越来越多的证据支持替奈普酶作为阿替普酶的替代药物，具有许多潜在的益处。本文讨论了静脉再灌注的现有证据，并考虑了改善获得途径的策略，包括对与疗效相关的监管更新进行可能的修改。
Zotero 插件